170 related articles for article (PubMed ID: 24145282)
1. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.
Liu XF; Xiang L; FitzGerald DJ; Pastan I
Mol Cancer Ther; 2014 Jan; 13(1):82-9. PubMed ID: 24145282
[TBL] [Abstract][Full Text] [Related]
2. Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.
Liu X; Müller F; Wayne AS; Pastan I
Mol Cancer Ther; 2016 May; 15(5):1053-62. PubMed ID: 26939705
[TBL] [Abstract][Full Text] [Related]
3. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
Hassan R; Broaddus VC; Wilson S; Liewehr DJ; Zhang J
Clin Cancer Res; 2007 Dec; 13(23):7166-71. PubMed ID: 18056197
[TBL] [Abstract][Full Text] [Related]
4. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
[TBL] [Abstract][Full Text] [Related]
5. The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.
Liu XF; FitzGerald DJ; Pastan I
Cancer Res; 2013 Apr; 73(7):2281-8. PubMed ID: 23348423
[TBL] [Abstract][Full Text] [Related]
6. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.
Du X; Xiang L; Mackall C; Pastan I
Clin Cancer Res; 2011 Sep; 17(18):5926-34. PubMed ID: 21813632
[TBL] [Abstract][Full Text] [Related]
7. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
[TBL] [Abstract][Full Text] [Related]
9. Improving the
Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
[TBL] [Abstract][Full Text] [Related]
10. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.
Zhang Y; Xiang L; Hassan R; Pastan I
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17099-104. PubMed ID: 17940013
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.
Ali-Rahmani F; FitzGerald DJ; Martin S; Patel P; Prunotto M; Ormanoglu P; Thomas C; Pastan I
Cancer Res; 2016 Mar; 76(6):1560-8. PubMed ID: 26719540
[TBL] [Abstract][Full Text] [Related]
12. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
Bang S; Nagata S; Onda M; Kreitman RJ; Pastan I
Clin Cancer Res; 2005 Feb; 11(4):1545-50. PubMed ID: 15746059
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
Hassan R; Bullock S; Premkumar A; Kreitman RJ; Kindler H; Willingham MC; Pastan I
Clin Cancer Res; 2007 Sep; 13(17):5144-9. PubMed ID: 17785569
[TBL] [Abstract][Full Text] [Related]
14. Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Leshem Y; O'Brien J; Liu X; Bera TK; Terabe M; Berzofsky JA; Bossenmaier B; Niederfellner G; Tai CH; Reiter Y; Pastan I
Cancer Immunol Res; 2017 Aug; 5(8):685-694. PubMed ID: 28674083
[TBL] [Abstract][Full Text] [Related]
15. Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells.
Hollevoet K; Antignani A; Fitzgerald DJ; Pastan I
J Immunother; 2014 Jan; 37(1):8-15. PubMed ID: 24316551
[TBL] [Abstract][Full Text] [Related]
16. Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.
Kaplan G; Lee F; Onda M; Kolyvas E; Bhardwaj G; Baker D; Pastan I
Toxins (Basel); 2016 Jul; 8(8):. PubMed ID: 27463727
[TBL] [Abstract][Full Text] [Related]
17. Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.
Mattoo AR; Pastan I; Fitzgerald D
PLoS One; 2013; 8(10):e75576. PubMed ID: 24130723
[TBL] [Abstract][Full Text] [Related]
18. Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine.
Liu XF; Wei J; Zhou Q; Molitoris BA; Sandoval R; Kobayashi H; Okada R; Nagaya T; Karim B; Butcher D; Pastan I
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6086-6091. PubMed ID: 32123080
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of Immunotoxins Containing
Mazor R; Pastan I
Front Immunol; 2020; 11():1261. PubMed ID: 32695104
[TBL] [Abstract][Full Text] [Related]
20. Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts.
Hassan R; Williams-Gould J; Steinberg SM; Liewehr DJ; Yokokawa J; Tsang KY; Surawski RJ; Scott T; Camphausen K
Clin Cancer Res; 2006 Aug; 12(16):4983-8. PubMed ID: 16914588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
